medigraphic.com
ISSN 1684-1824 (Electronic)

2016, Number 4

<< Back Next >>

Rev Méd Electrón 2016; 38 (4)

Recurrent laryngeal papilomatosis with multidiscipline followup. A propos of a case

Barrera RD, Arnold AML, Peña CCL, Alfonso RJ

Language: Spanish
References: 20
Page: 595-601
PDF size: 225.55 Kb.


ABSTRACT

Laryngeal papillomatosis is a disease produced by the human papillomavirus, frequently affecting the vocal cords, epiglottis, and also the ventricular bands, that may extend to the entire organ. The disease has an unpredictable course and the pulmonary extension and malignant transformation has been reported. In the clinicsurgical otorhinolaryngological practice it is a challenge to achieve an adequate manage of the patient when the evolution tends to recidivisms. The case of a female patient aged 53 years was presented; she had no record of previous disease, and was diagnosed of laryngeal papillomatosis, being treated with human recombinant Interferon 82b and laryngeal microsurgeries. In a period of 4 months, she presented 6 recidivisms: the first five of them mediated by 10-15 days, and the 6ths one a month after the precedent. The sequence used for the study was enounced, including the dosage of interferon antibodies, serologic studies searching for concomitance with other viruses, viral typing, dosage of immunoglobulins and complements. Besides that, it was carried out a proposal of clinical follow-up taking into account the lesions status and level. It was evidenced the importance of the multidiscipline management of the patient by immunologists, infection diseases specialists, otolaryngologists and phoniatrists for his/her total recuperation.


REFERENCES

  1. 1- Vaughn JA, Miller RA. Update on Immunizations in Adults. Am Fam Physician. 2011 Nov 1;84(9):1015-20. Citado en PubMed; PMID: 22046942.

  2. 2- Mc Murray JS, Connor N, Ford CN. Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. An Otol Rhinol Laryngol. 2008;117(7):477-83. Citado en PubMed; PMID: 18700421.

  3. 3- Center for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60(50):1705-8. Citado en PubMed; PMID: 22189893.

  4. 4- Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope. 2008;118(7):1236-47. Citado en PubMed; PMID: 18496162 .

  5. 5- Gallagher TQ, Derkay CS. Recurrent respiratory papillomatosis: update 2008. Curr Opin Otolaryngol Head Neck Surg. 2008;16(6):536-42. Citado en PubMed; PMID: 19005325.

  6. 6- Kim LY , Cohen NA , Palmer JN , et al. Bacteriology of inverted papilloma. Rhinology. 2014 Dec;52(4):366-70. Citado en PubMed; PMID: 25479216.

  7. 7- Committee on Infectious Diseases. HPV Vaccine Recommendations. Pediatrics. 2012;129(3):602-5. Citado en PubMed; PMID: 22371460.

  8. 8- Goldman L, Schafer AI, editors. Goldman's Cecil Medicine. Philadelphia: Elsevier/Saunders; 2012. p. 2121-5.

  9. 9- Chang F, Syrjanen S, Shen Q, Cintorino M, et al. Human papillomavirus involvement in esophageal carcinogenesis in the high incidence area of China - a study of 700 cases by screening and type specific in situ hybridization. Scand J Gastroenterol [Internet]. 2000 [citado 3 May 2015];35(2):123-30. Disponible en http://informahealthcare.com/doi/abs/10.1080/003655200750024272

  10. 10- Patient UK . Egton Medical Information Systems. Nasal polyps [Internet]. 2014 Nov 10 [citado 23 Ene 2015]. Disponible en: http://www.patient.co.uk/health/Nasal-Polyps.htm

  11. 11- National Advisory Committee on Inmunization. Update on human papillomavirus (HPV) vaccines. Can Commun Dis Resp. 2012;38(1).

  12. 12- INFOVAC. Vaccionation against HPV. Change from three-dose schedule to a two dose schedule for adoles-cents under 15 years of age. Bulletin [Internet]. 2012 Feb [citado 23 Ene 2015]. Disponible en: http://www.infovac.ch

  13. 13- Safaeian M, Porras C, Pan Y, Kreimer A, et al. Inmunogenecity following one and two doses of HPV-16/18 vaccine suggests longevity of responses; results from the Costa Rica HPV 16/18 Vaccine Trial (CVT). Conferencia presentada en: 28 th International Papillomavirus Conference and Clinical and Public Health Workshops; 30 Nov-6 Dec. 2012. San Juan: Conference and Clinical and Public Health Workshops; 2012.

  14. 14- Alfonso Morales Fuentes G, De Ariño Suárez M, Zárate Osorno A, et al. Pólipo de Vanek o pólipo fibroide inflamatorio. Informe de un caso y revisión de la literatura. Cir Cir [Internet]. 2011 [citado 12 Ene 2015];79(3). Disponible en: http://www.redalyc.org/articulo.oa?id=66220802009

  15. 15- Dobson S, Dawar M, Kollmann T, et al. A two dose HPV vaccine schedule in girls: immunogenicity at 24 months IPC. Sesión de póster presentado en Montreal; 3-8 July 2010. Montreal; 2010.

  16. 16- León Espinoza C, Gómez Mateo M, López Mozos F, et al. Does Adult Intestinal Invagination Need Surgery? Report of a Case and Review of Literature. International J Clin Med [Internet]. 2011 [citado 12 Ene 2015];2(4). Disponible en: http://file.scirp.org/Html/16-2100098_7559.htm

  17. 17- Gutu E, Ghidirim G, Misin I, Iakovleva I, Vozian M. Bleeding gastric inflammatory fibroid polyp (Vanek's tumor). Chirurgia (Bucur). 2010; 105(1):137-40. Citado en PubMed; PMID: 20405696.

  18. 18- Avelino M, Pontes P, Weckx L. Proposta de estadiamento topográfico para papilomatose laríngea. Rev Bras Otorrinolaringol. 2003;69(4):452-6. Citado en LILACS; ID: 344932.

  19. 19- Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011 Oct 5;103(19):1444-51. Citado en PubMed; PMID: 21908768.

  20. 20- International Agency for Research on Cancer [Internet]. Ginebra: World Health Organization; c 2015. [citado 1 mar 2015]. Disponible en: http://screening.iarc.fr/hpvvaccine.php




2020     |     www.medigraphic.com